The Trump administration has limited guidance documents, a move that could curb the government’s ability to sue companies accused of violations. The change could significantly affect the healthcare and life sciences industries, as the Food and Drug Administration and Centers for Medicare and Medicaid Services rely on guidance documents. (The New York Times)

David Hung has stepped down as CEO of Axovant. The Alzheimer’s company’s COO and three members of its board of directors have also left. Axovant has had a rough few months: the one piece of promising data from its 5HT6 drug turned out to be a statistical error. (Endpoints News)

President Donald Trump has nominated White House deputy chief of staff Jim Carroll as drug czar. As the head of the Office of Drug Control Policy, Carroll, who does not have previous public health experience, would be charged with fighting the opioid crisis. (STAT)

FDA Commissioner Scott Gottlieb has won over some critics as he seeks to balance the agency’s mission with the interests of Big Pharma, but not all. Gottlieb has walked a fine line in the last nine months, simultaneously protecting public health and scratching the industry’s back. (The New York Times)

#MeToo upends the advertising industry. A number of high-profile execs have left their agencies in the past couple of months amidst a flurry of sexual harassment allegations. Departures have hit Martin Agency, Publicis, Wieden+Kennedy, and Droga5, among other firms. (Quartz)